CD4 and neoplasm: cDC1 reprogramming synergized with anti-PD-1 or anti-CTLA-4 treatment leading to increased CR in B16 and B2905, which also resulted in expansion of tumor antigen-specific IFNγ+CD8+ and IFNγ+CD4+ T cells in peripheral blood (Fig. 1C).